Although both HER2-positive and HER2-low expression are suitable for T-DXd, HER2-positive breast cancers may benefit more significantly due to the high level of HER2 protein expression, with which T-DXd binds more efficiently to exert its targeting effect. This evidence concerns the gene ERBB2 and breast cancer.